Giampaolo Bianchini, Head of Clinical Translational and Immunotherapy Research at Ospedale San Raffaele, shared a post on X:
“Abema + fulvestrant after 1L CDK4/6i/AI improves PFS, PFS2 and time to chemo; numerical ↑OS
CDK targeting remains valid post-CDK4/6i, but NOT a class effect!
Effective: Abema (postMONARCH, EMBER-3), atirmociclib (FourLight-1), ribo (MAINTAIN)
Ineffective: Palbo (PACE, PALMIRA).”
You can also read: postMONARCH: Abemaciclib Shows Numerically Longer Overall Survival After Prior CDK4/6 Inhibition
